Please login to the form below
Antibody cocktail
This page shows the latest Antibody cocktail news and features for those working in and with pharma, biotech and healthcare.
Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
Regeneron has ended four clinical trials of its monoclonal antibody combination, REGEN-COV (casirivimab and imdevimab), according to the federal clinical trial database. ... Regeneron invented the antibody cocktail and is collaborating with Roche, the
Latest news
-
Celltrion submits application for inhaled COVID-19 antibody treatment
A global phase 3 clinical study will evaluate the inhaled antibody cocktail treatment for patients with mild-to-moderate COVID-19 symptoms. ... Celltrion has announced that it has submitted an Investigational New Drug (IND) application for its inhaled
-
Roche’s Actemra approved for severe COVID-19 in Europe
The monoclonal antibody previously used to treat inflammatory conditions such as rheumatoid arthritis is already being used in the US and Australia. ... The EMA approved Roche/Regeneron’s antibody cocktail, Ronapreve (casirivimab/imdevimab), in November
-
MHRA approves second COVID-19 antibody treatment
The UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has approved a second antibody treatment against COVID-19. ... Like Regeneron/Roche antibody cocktail Ronapreve (casirivimab/imdevimab), known as REGEN-COV in the US,
-
Regeneron’s COVID-19 antibody cocktail approved in Europe
Following a positive recommendation from its medicines committee, the European Medicines Agency (EMA) has approved Regeneron’s antibody cocktail, Ronapreve (casirivimab/imdevimab). ... For non-hospitalised infected individuals, our antibody cocktail
-
Regeneron’s antibody cocktail REGEN-COV offers sustained protection against COVID-19
Regeneron’s antibody cocktail REGEN-COV (casirivimab and imdevimab) has demonstrated sustained protection against infection by SARS-CoV-2, the coronavirus that causes COVID-19, over an eight-month period.
More from news
Approximately 2 fully matching, plus 38 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
